Connection

Gabriel Virella to Antigen-Antibody Complex

This is a "connection" page, showing publications Gabriel Virella has written about Antigen-Antibody Complex.
Connection Strength

3.532
  1. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages. Clin Immunol. 2018 02; 187:1-9.
    View in: PubMed
    Score: 0.565
  2. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J Atheroscler Thromb. 2013; 20(10):743-54.
    View in: PubMed
    Score: 0.431
  3. Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes. J Immunoassay Immunochem. 2013; 34(1):61-74.
    View in: PubMed
    Score: 0.413
  4. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol. 2008 Jun; 127(3):394-400.
    View in: PubMed
    Score: 0.300
  5. Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol. 2005 Jan; 12(1):68-75.
    View in: PubMed
    Score: 0.237
  6. Immune Complexes and the Risk of CVD in Type 1 Diabetes. Diabetes. 2019 09; 68(9):1853-1860.
    View in: PubMed
    Score: 0.162
  7. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes. J Diabetes Complications. 2016 May-Jun; 30(4):693-9.
    View in: PubMed
    Score: 0.127
  8. Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes. J Lipid Res. 2014 May; 55(5):860-9.
    View in: PubMed
    Score: 0.112
  9. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis. 2012 Oct; 224(2):526-31.
    View in: PubMed
    Score: 0.101
  10. Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb. 1991 Sep-Oct; 11(5):1356-67.
    View in: PubMed
    Score: 0.094
  11. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrol Dial Transplant. 2012 Apr; 27(4):1416-23.
    View in: PubMed
    Score: 0.094
  12. Oxidized LDL immune complexes stimulate collagen IV production in mesangial cells via Fc gamma receptors I and III. Clin Immunol. 2011 Jun; 139(3):258-66.
    View in: PubMed
    Score: 0.091
  13. Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxidative stress. PLoS One. 2010 Sep 02; 5(9).
    View in: PubMed
    Score: 0.088
  14. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complications. 2011 Mar-Apr; 25(2):73-82.
    View in: PubMed
    Score: 0.086
  15. Heat shock protein 70B' (HSP70B') expression and release in response to human oxidized low density lipoprotein immune complexes in macrophages. J Biol Chem. 2010 May 21; 285(21):15985-93.
    View in: PubMed
    Score: 0.085
  16. Clinical significance of the humoral immune response to modified LDL. Clin Immunol. 2010 Jan; 134(1):55-65.
    View in: PubMed
    Score: 0.080
  17. Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis. 2009 Feb; 202(2):394-404.
    View in: PubMed
    Score: 0.075
  18. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res. 2006 Sep; 47(9):1975-83.
    View in: PubMed
    Score: 0.066
  19. The immunogenicity of modified lipoproteins. Ann N Y Acad Sci. 2005 Jun; 1043:367-78.
    View in: PubMed
    Score: 0.061
  20. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res. 2004 Oct; 45(10):1859-67.
    View in: PubMed
    Score: 0.057
  21. Role of simvastatin as an immunomodulator in type 2 diabetes. Diabetes Care. 2004 Apr; 27(4):908-13.
    View in: PubMed
    Score: 0.056
  22. Humoral immunity and atherosclerosis. Nat Med. 2003 Mar; 9(3):243-4; author reply 244-5.
    View in: PubMed
    Score: 0.052
  23. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes. 2000 Jun; 49(6):1033-41.
    View in: PubMed
    Score: 0.043
  24. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis. 2007 Feb; 190(2):359-69.
    View in: PubMed
    Score: 0.016
  25. Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort. Nephrol Dial Transplant. 2006 Jan; 21(1):93-100.
    View in: PubMed
    Score: 0.016
  26. Chlamydophila pneumoniae infection of human aortic endothelial cells induces the expression of FC gamma receptor II (FcgammaRII). Clin Immunol. 2002 Sep; 104(3):265-73.
    View in: PubMed
    Score: 0.013
  27. Erythrocyte-bound low-density lipoprotein immune complexes lead to cholesteryl ester accumulation in human monocyte-derived macrophages. Clin Immunol Immunopathol. 1991 Apr; 59(1):37-52.
    View in: PubMed
    Score: 0.006
  28. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med. 1988 Sep 01; 168(3):1041-59.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.